mTOR inhibitors are associated with hypophosphatemia, and monitoring is recommended monthly for mild hypophosphatemia, weekly for moderate hypophosphatemia, and daily for severe hypophosphatemia, with no recommendation for initial phosphate measurement [35]. This evidence concerns the gene MTOR and hypophosphatemia.